Streetbeat News

KTTA

Pasithea Therapeutics Corp.

https://www.pasithea.com

Industry

Biotechnology

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Open

3.42

Mkt cap

3.5M

Volume

22K

High

3.42

P/E Ratio

-0.23

52-wk high

17.40

Low

3.19

Div yield

N/A

52-wk low

3.19

Pasithea Therapeutics has completed long-term chronic toxicity studies for its lead candidate PAS-004, a MEK inhibitor, in rats and dogs. The studies confirm a consistent safety profile, supporting ongoing Phase 1 trials in advanced cancer patients.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:20 pm

Pasithea Therapeutics announced that an independent safety review committee has completed a safety review of data from the first dose cohort in the Phase 1 trial of PAS-004.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 11:07 am

The article highlights significant intraday movements in health care stocks on Tuesday. Notable gainers include Concord Medical Services (NYSE:CCM), Annexon (NASDAQ:ANNX), and Olema Pharmaceuticals (NASDAQ:OLMA). Significant losers include ENDRA Life Sciences (NASDAQ:NDRA), Equillium (NASDAQ:EQ), and Microbot Medical (NASDAQ:MBOT).

Portfolio Pulse from Benzinga Insights

June 04, 2024 | 4:31 pm

Pasithea Therapeutics announced new preclinical data showing that PAS-004 strongly inhibits NRAS cancer cell lines.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 11:01 am

The article highlights significant intraday movements in health care stocks on Friday. Akanda, NovaBay Pharmaceuticals, Pasithea Therapeutics, TransCode Therapeutics, Onconetix, and Doximity saw notable gains, while Lucy Scientific Discovery, SINTX Techs, Bone Biologics, ARCA biopharma, Cardio Diagnostics Holdings, and Sonoma Pharmaceuticals experienced declines.

Portfolio Pulse from Benzinga Insights

May 17, 2024 | 4:31 pm

Pasithea Therapeutics Corp. (NASDAQ:KTTA) announced its PAS-004 abstract has been accepted for a poster presentation at the 2024 ASCO Annual Meeting. PAS-004, a novel macrocyclic MEK inhibitor, shows promise in treating neurofibromatosis type 1 (NF1) and potentially other diseases by inhibiting cancer cell growth. The drug aims to offer better compliance, efficacy, and safety profiles compared to existing MEK inhibitors, with preclinical studies and animal toxicology completed and an FDA orphan-drug designation received for NF1 treatment.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 12:14 pm

Pasithea Therapeutics shares have resumed trading after a temporary halt. The resumption of trading allows investors to buy and sell Pasithea Therapeutics stock once again.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 2:00 pm

Pasithea Therapeutics has announced that the FDA has accepted its Investigational New Drug (IND) application for PAS-004, which is intended for evaluation in advanced cancer patients. This acceptance marks a significant milestone for the company as it can now proceed with clinical trials to assess the safety and efficacy of PAS-004 in this patient population.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 1:39 pm

Trading on KTTA was halted at 7:50:00 p.m. ET due to pending news. The halt is in place to manage market orderliness and investor protection pending the release of material news.

Portfolio Pulse from Benzinga Newsdesk

December 30, 2023 | 12:50 am

Pasithea Therapeutics Corp (KTTA) announced a 1-for-20 reverse stock split effective January 2, 2024. The reverse split will reduce the number of authorized shares from 495 million to 100 million and will adjust all outstanding securities accordingly. Fractional shares will not be issued; instead, shareholders will receive a cash payment. The reverse split aims to maintain the company's stock price above the minimum required by Nasdaq and potentially improve marketability and liquidity.

Portfolio Pulse from Benzinga Newsdesk

December 28, 2023 | 4:41 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.